This is an open-label, multi-center, single-arm, two-period phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or persistent endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative. All patients must have endometrial cancer PrR status determined from an archival sample at screening. The PrR status (positive or negative) will be determined by central laboratory by IHC testing.
There are two treatment periods and a follow-up period within the study.